An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Trial Profile

An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Pomalidomide; Prednisone; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms EQUULEUS
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Sep 2017 Results (n=32) presented at the 42nd European Society for Medical Oncology Congress
    • 17 Aug 2017 Planned primary completion date changed from 30 Jun 2017 to 27 Oct 2018.
    • 25 Jun 2017 Results (n=22) assessing the tolerability and efficacy of Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma presented the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top